ReviewCurrent opinion in HIV and AIDS2015
Vectored antibody gene delivery for the prevention or treatment of HIV infection.
Review in Current opinion in HIV and AIDS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Structure and sequence engineering approaches to improve in vivo expression of nucleic acid-delivered antibodies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.Frontiers in immunology · 2021Review
- Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection.Molecular therapy. Methods & clinical development · 2020Article
- Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.Molecular therapy. Methods & clinical development · 2020Article
- Construction of Antibody Phage Libraries and Their Application in Veterinary Immunovirology.Antibodies (Basel, Switzerland) · 2020Review
- AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region.Molecular therapy. Methods & clinical development · 2019Article
- Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge.PLoS pathogens · 2018Article
- Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Nature reviews. Immunology · 2018Review
- Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.Frontiers in immunology · 2018Review
- Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System.Current HIV/AIDS reports · 2017Review
- HIV antibodies for treatment of HIV infection.Immunological reviews · 2017Review
- Engineering broadly neutralizing antibodies for HIV prevention and therapy.Advanced drug delivery reviews · 2016Review
- New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Expert review of vaccines · 2016Review
- Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.Nature communications · 2016Article
- Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Frontiers in immunology · 2016Review
- Increased frequencies of CD8Journal of the International AIDS Society · 2016Article
- Article
- Review
- Therapeutic Antibody Discovery in Infectious Diseases Using Single-Cell Analysis.Advances in experimental medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewTo discuss recent progress in the use of vectors to produce antibodies in vivo as an alternative form of HIV prophylaxis or therapy. Instead of passive transfer of monoclonal antibody proteins, a transgene encoding an antibody is delivered to cells by the vector, resulting in expression and secretion by the host cell. This review will emphasize adeno-associated virus (AAV)-based strategies and summarize the evidence in support of this strategy as an alternative to traditional vaccines. We will highlight the major findings in the field and discuss the impact that this approach could have on the prevention, treatment and possibly eradication of HIV in patients. RECENT
findingsIn this emerging field, the emphasis has been on the use of vectors delivering antibodies as an alternative to the development of an HIV vaccine. However, recent findings suggest that AAV-delivered broadly neutralizing antibodies can suppress HIV replication. As such, a single injection of AAV could mediate long-term antibody expression to act as a long-lived therapeutic in the absence of antiretroviral drugs. SUMMARY: Vector-mediated antibody expression can both prevent transmission and inhibit the replication of established HIV infections. As such, it offers an alternative to immunogen-based vaccine design and a novel therapeutic intervention by enabling precise manipulation of humoral immunity. Success may enable not only the development of effective prevention against HIV but may also provide an alternative to a lifetime of antiretroviral drugs taken by those who are already infected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.